Overview

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.

Phase:

PHASE2

Details

Lead Sponsor:

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics